Resources
5 Results (showing 1 - 5)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 12/18/2023 (updated 3/28/2024)
This study looks at perinatal care for pregnant people with substance use disorders. Stigma and lack of access to treatment and recovery increases the risk for pregnant people. Results and suggestions from the study include the need to expand OUD treatment training, clarification on child welfare reporting rules, the need to include philanthropic investment, and more.
Posted 8/31/2022 (updated 3/27/2024)
The study explored opportunities for enhanced screening using telehealth and electronic patient-reported outcomes at five HRSA-funded Ryan White HIV/AIDS Program clinics in Alabama – one of seven mostly rural states prioritized for the federal Ending the HIV Epidemic Initiative. While there were concerns among survey respondents around lack of in-person interaction, the study revealed opportunities to expand technology use in rural areas.
Posted 5/3/2022 (updated 3/27/2024)
Buprenorphine utilization is an effective treatment for opioid use disorder (OUD). Given the recent
increase in child maltreatment reports related to parental substance use, research should explore the correlation between buprenorphine treatment and child maltreatment–related outcomes.
Posted 10/13/2021 (updated 4/3/2024)
Over the past twenty years a large number of new psychoactive substances (NPS) have entered and modified the recreational drug scene. Their intake has been associated with health-related risks, especially so for vulnerable populations such as people with severe mental illness, who might be at higher risk of suicidality or self-injurious behavior. This paper aims at providing an overview of NPS abuse and the effects on mental health and suicidality issues, by performing a literature review of the current related knowledge, thereby identifying those substances that, more than others, are linked to suicidal behaviors.
Posted 4/19/2021 (updated 4/5/2024)
The present article reviews whether available efficacy and safety data support the pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD) in patients with concurrent substance use disorders (SUD). Arguments for and against treating adult ADHD with active SUD are discussed